Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central nervous process, conolidine modulates alternate molecular targets. A Science Innovations study discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://guyi527epz8.worldblogged.com/profile